Integrated Cancer Research Site

PATHEX platform: experimental pathology

SIRIC team
Institut Curie's PATHEX experimental pathology platform performs tissue analyzes for basic and translational research projects
Equipe de la plateforme PATHEX (pathologie expérimentale)

Experimental pathology

  • Pathology is the medical speciality dedicated to morphological analysis of cell and tissue lesions for diagnostic, prognostic, predictive and theranostic purposes.
  • Experimental pathology is the field of pathology more particularly dedicated to the investigation of the biological and physical mechanisms at the origin of syndromes and diseases. 

An integrated experimental pathology platform at the heart of the Diagnostic and Theranostic Medecine Division (PMDT)

The PATHEX platforme is integrated in the diagnostic and theranostic medicine division (PMDT) bringing together the pathology, genetics, immunology and hemobiology departments of the Institut Curie Hospital Complex. The strength of the division is the synergy of expertises between different departments as well as strong links with the Research Center for each signature speciality of the hospital (senology, ophthalmology, pediatrics, gynecology, soft tissue sarcomas...). 

Integrated at the heart of the PMDT and in close relation with the Research Center teams, the PATHEX platform ensures a permanent technological watch responding to the increasing complexity of current cancer research investigation fields (immuno-oncology, epigenetics, genomics...). The platform also regularly ensures the implementation of innovative tissue technologies coupled with artificial intelligence software tools which carries out quantitative and multiparametric tissue analyses. 


  • Perform histological analyzes of research projects 
  • Offer innovative techniques through technological watch (quantitative and multi-parametric tissue analyzes with artificial intelligence) 
  • Develop partnerships with the biopharmaceutical industrie for the validation of biomarkers as well as new therapeutic vectors (nanobodies, CAR-T cells)
  • Support students and researchers from Institut Curie, other institutions and biopharmaceutical institutions to carry out morphological techniques and the interpretation of results on animal tissues (transgenic mice, xenografts,...) and human samples (tissues, cell cultures, liquids). 

Available techniques

Experimental pathology

  • RNA FISH (RNAscope) and DNA-FISH
  • Multiplexed chromogenic immunohistochemistry with quantitative image analysis
  • Multiplexed fluorescent immunohistochemistry with quantitative image analysis
  • Production of custom antibody panels
  • Immunoligation (PLA, proximity ligation assay)
  • "NGS in situ" in partnership: DSP (Nanostring in situ technology) and Hyperion (Immunomicroscopy by mass spectrometry)
  • Preparation of cell blocks, multi-tissue blocks (TMA), sections for histological and immunohistochemical analyzes, macrodissection and thick sections, microdissection, immunostaining on paraffin and frozen sections
  • Analysis and characterization of human tumors, xenografts and murine models

Techniques de la plateforme PATHEX

Digital pathology

  • Digitization of histological samples
  • Normalized image analysis
  • Setting up a bank of virtual slides
  • High definition image production: JPEG, PNG, TIF, BIGTIF, SVS

Equipements de pointe

  • 2 TMA arrayers
  • 2 Leica BOND RX immunohistochemistry automats
  • 1 VECTRA PerkinElmer quantitative multispectral imaging platform
  • 1 HALO Indica Labs image analysis platform
  • Philips UFS scanner
  • Metadata analysis software with Artificial Intelligence (FIJI / ImageJ, Inform / PerkinElmer, Tissue Studio / Definiens).

Equipements de la plateforme PATHEX

Standard equipment

  • Leica microdissector, optical microscopes, cryostat multitead optical microscope, HistoCore Leica PEARL impregnation machine, microtome, Valida MEDIT embedding station


Pour any requests or proposals:

Selection of publications

  • PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer. Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S,  Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I. Oncotarget 2018;9:23208-23219.
  • High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism. Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M. PLoS One 2018;13:e0190619. doi: 10.1371/journal.pone.0190619.
  • Clinical value of R-spondins in triple-negative and metaplastic breast cancers. Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I. Br J Cancer 2017;116:1595-1603.
  • Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer. Mameri H, Bièche I, Meseure D, Marangoni E, Buhagiar-Labarchède G, Nicolas A, Vacher S, Onclercq-Delic R, Rajapakse V, Varma S, Reinhold WC, Pommier Y,Amor-Guéret M. Clin Cancer Res 2017;23:2116-2126.
  • The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages. Bougherara H, Némati F, Nicolas A, Massonnet G, Pugnière M, Ngô C, Le Frère-Belda MA, Leary A, Alexandre J, Meseure D, Barret JM, Navarro-Teulon I,Pèlegrin A, Roman-Roman S, Prost JF, Donnadieu E, Decaudin D. Oncotarget 2017;8:99950-99965.
  • The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Han ZY, Richer W, Fréneaux P, Chauvin C, Lucchesi C, Guillemot D, Grison C, Lequin D, Pierron G, Masliah-Planchon J, Nicolas A, Ranchère-Vince D, Varlet P, Puget S, Janoueix-Lerosey I, Ayrault O, Surdez D, Delattre O, Bourdeaut F. Nat Commun. 2016 Jan 28;7:10421. doi: 10.1038/ncomms10421.
  • Expression of ANRIL - Polycomb Complexes - CDKN2A/B/ARF Genes in Breast Tumors: Identification of a Two-gene (EZH2/CBX7) Signature with Independent Prognostic Value. Meseure D, Vacher S, Drak Alsibai K, Nicolas A, Chemlali W, Caly M, Lidereau R, Pasmant E, Callens C, Bieche I. Mol Cancer Res 2016.
  • TIPIN depletion leads to apoptosis in breast cancer cells. Baldeyron C, Brisson A, Tesson B, Némati F, Koundrioukoff S, Saliba E, De Koning L, Martel E, Ye M, Rigaill G, Meseure D, Nicolas A, Gentien D, Decaudin D, Debatisse M, Depil S, Cruzalegui F, Pierré A, Roman-Roman S, Tucker GC, Dubois T. Mol Oncol 2015;9:1580-98.
  • Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Wassef M, Rodilla V, Teissandier A, Zeitouni B, Gruel N, Sadacca B, Irondelle  M, Charruel M, Ducos B, Michaud A, Caron M, Marangoni E, Chavrier P, Le Tourneau C, Kamal M, Pasmant E, Vidaud M, Servant N, Reyal F, Meseure D, Vincent-Salomon A, Fre S, Margueron R. Genes Dev 2015;29:2547-62.
  • The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma. Montes de Oca R, Gurard-Levin ZA, Berger F, Rehman H, Martel E, Corpet A, de Koning L, Vassias I, Wilson LO, Meseure D, Reyal F, Savignoni A, Asselain B, Sastre-Garau X, Almouzni G. Mol Oncol 2015;9:657-74.
  • Concomitant Notch activation and p53 deletion trigger epithelial-to-mesenchymal transition and metastasis in mouse gut. Chanrion M, Kuperstein I, Barrière C, El Marjou F, Cohen D, Vignjevic D, Stimmer L, Paul-Gilloteaux P, Bièche I, Tavares Sdos R, Boccia GF, Cacheux W, Meseure D, Fre S, Martignetti L, Legoix-Né P, Girard E, Fetler L, Barillot E, Louvard D, Zinovyev A, Robine S. Nat Commun 2014;5:5005. doi: 10.1038/ncomms6005.
  • Tubulin glycylases are required for primary cilia, control of cell proliferation and tumor development in colon. Rocha C, Papon L, Cacheux W, Marques Sousa P, Lascano V, Tort O, Giordano T, Vacher S, Lemmers B, Mariani P, Meseure D, Medema JP, Bièche I, Hahne M, Janke C. EMBO 2014;33:2247-60.


- Anne Vincent-Salomon, head of the Diagnostic and Theranostic Medicine division

- Yves Allory, head of Pathology for the Saint-Cloud site

- Didier Meseure, medical manager of the PATHEX platform

- André Nicolas, responsible for the technical and logistical management of the PATHEX platform

- Scientific consultant: Sergio Roman Roman, head of the translational research department and director of the SIRIC


The platform’s permanent staff is made up of study engineers (Renaud Leclere, Laetitia Lesage, Gabriel Champenois), a technician (Mallory Brousse) and an image analysis engineer (Faezeh Moazami).

The results are analyzed by the platform pathologist and by organ pathologists from the Pathology Department in the event of specific expertise required (senology, pediatrics, soft tissue sarcomas, gynecology, uveal melanomas, ENT, urology. ).